A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

To join this study, you must be at least 18 years old and have small cell lung cancer that has spread and has come back after only one previous course of platinum-based chemotherapy. Your cancer must have been confirmed by a biopsy, and you need to have cancer that can be measured on scans.

There are also some important health checks. You need to be generally well enough to take part, with a good level of physical activity. Doctors will also check that you don't have certain other health issues or active brain cancer that requires immediate treatment. You also can't have been treated with certain related drugs before.

If you decide to join this study, you'll first have some assessments to confirm you're eligible. Once enrolled, you'll be randomly assigned to receive either the new study drug (ifinatamab deruxtecan) or one of the standard treatments for your type of cancer. You won't get to choose which treatment you receive, and neither will your doctor.

The treatment will involve regular visits to the clinic for your medication and various tests, such as blood tests, scans to check your cancer, and physical exams. You'll also be asked to complete questionnaires about how you're feeling and how the treatment is affecting your quality of life. The study duration will vary depending on your treatment and how your body responds, but you will have regular follow-up appointments even after treatment ends to monitor your health and the cancer's status.